Inmunoterapia en el tratamiento del cáncer de cabeza y cuello

4 / 52

4
FDA Grants Nivolumab Breakthrough Designation for Head and Neck Cancer
Published Online: Monday, Apr 25, 2016
The FDA has granted a breakthrough therapy designation to nivolumab
(Opdivo) as a treatment for patients with recurrent or metastatic squamous cell
carcinoma of the head and neck (SCCHN) following a platinum-based therapy,
according to the developer of the PD-1 inhibitor Bristol-Myers Squibb
The FDA is expected to act on the review by Nov. 11, 2016, according to a
from Bristol-Myers Squib, makers of nivolumab.
19 Apr 2016